

## SUPPLEMENTARY INFORMATION

### Impact of Delta and Vaccination on SARS-CoV2 transmission risk: Lessons for Emerging Breakthrough infections

Kalpana Sriraman, Ambreen Shaikh, Smriti Vaswani, Tejal Mistry, Grishma Patel, Shalini Sakthivel, Vikas Oswal, Pratibha Kadam, Kayzad Nilgiriwala, Daksha Shah, Mangala Gomare, Nerges Mistry

**Supplementary Table 1** – Comparison of patient clinical parameters, COVID-19 symptom characteristics stratified based on vaccination status

Descriptions	Overall	Cs-D1	Cs-D2	Cx-D2	Unvaccinated
<b>Clinical parameters</b>					
Lymphocytes (%) (median + IQR)	33 (26.7-39.1)	34 (29.5 - 39.5)	29 (17-38)	34.5 (27.5 - 44)	32 (26-35)
Platelets (thou/ $\mu$ L) (median + IQR)	253 (187-300)	286 (232 -314)	240 (177-288)	236 (174- 307)	271 (179-509)
Hemoglobin (g/dL) (median + IQR)	13.3 (11.7 -14.2)	13.5 (12.5 - 14)	13.4 (11.3 - 15.3)	13.4 (12.2 -14.1)	12.5 (11.6-13.6)
CRP (mg/L) (median + IQR)	7.8 (2.9 - 16)	7.75 (2.8 - 11)	10.2 (5.3- 20.3)	6.7 (2.6-18.1)	8.3 (1.71-13.1)
LDH (U/L) (median + IQR)	246 (173- 295)	209 (165 - 264)	256 (168- 280)	277 (189 -333)	NA
<b>Symptoms at Enrolment</b>					
Fever	44	16	11	13	4
Cough	55	18	13	17	6
Sore throat	25	10	5	7	1
Loss of Smell/Taste	51	13	14	17	7
Headache	15	4	5	3	3
Body ache/Weakness	27	10	4	9	3
Chills	7	1	1	4	1
Gastric Problems	5	0	2	1	2
Shortness of Breath	3	0	0	2	1
Cold	25	7	10	6	1
<b>Symptoms at Follow-up</b>					
Fever	2	0	0	2	0
Cough	37	12	7	14	4
Sore throat	4	0	1	1	2
Loss of Smell/Taste	37	8	11	15	3
Headache	6	1	1	4	0
Body ache/Weakness	6	1	0	5	0
Chills	1	0	0	1	0
Gastric Problems	6	1	1	4	0
Shortness of Breath	1	0	0	0	1
Cold	12	4	2	5	1
<b>Types of Comorbidities</b>					
Diabetes	14	0	9	4	1
Hypertension	9	0	5	2	2
Cardiovascular Disease	9	0	2	6	1
Others	14	4	2	6	2

All values are represented as the number of patients unless specified otherwise. Cs-D1 – One dose of Covishield, Cs-D2 - Two doses of Covishield and Cx-D2 – Two doses of COVAXIN; Ct value – cycle Threshold value; IQR – interquartile range. Cx-D1 group was not included in the analysis due to low patient number (N=2)

**Supplementary Table 2 – Viral strain of the sequenced patient samples**

SARS-CoV-2 strain	Number of Patients
Delta	66
Delta Derivative (AY.120)	9

**Supplementary Table 3 – Comparison between Mask High Viral Emitters and Not High Emitters\***

Descriptions	High Emitters (N=37)	Not High Emitters* (N=55)	p-value	Adjusted p-value (Multivariate Analysis)
<b>Age</b> (median + IQR)	40 (30-50)	41 (31-50)	0.761	0.115
<b>Gender</b>				
Male	23	28		
Female	14	27	0.392	
<b>Vaccine Status</b>				
Cs-D1	7	19	>0.999	0.475
Cs-D2	14	14	0.32	0.678
Cx-D1	1	1	>0.999	0.228
Cx-D2	11	13	0.49	0.893
Unvaccinated	4	9		
<b>Swab Ct Value at Diagnosis</b> (median + IQR)	20 (16-24)	21 (17-25.7)	0.305	0.091
<b>Swab Viral Load at Recruitment (log Value)</b> (median + IQR)	6.5 (5.6 – 7.5)	4.4 (2.7-5.6)	<0.0001	<b>0.027</b>  Adjusted for Age, Vaccine status, Number of comorbidities, Swab Ct value at Diagnosis, Cough as a symptom, Day's post symptom onset and effect of days post symptom onset and comorbidities on viral load
<b>Number of Symptoms</b>	4 (2-5)	3 (2-4)	0.341	
<b>Type of Symptoms</b>				
Fever	17	28	0.675	
High	3	4	>0.999	
Mild	15	25	0.673	
Cough	27	28	<b>0.038</b>	0.334
Sore Throat	12	13	0.473	
Loss of Smell and Taste	16	35	0.058	
Shortness of Breath	2	1	0.562	
Cold	12	13	0.473	
<b>Number of comorbidities</b>	1 (0-1)	0	<b>0.001</b>	0.976
<b>Type of comorbidities</b>				
Diabetes	9	5	0.073	
Hypertension	6	4	0.193	
CVD	4	1	0.153	
Others	8	6	0.236	
<b>Duration between last dose of vaccination to infection</b> (median + IQR)	47 (21-87)	58 (21-77)	0.707	
<b>Antivirals taken</b>	23	32	0.829	
<b>Days post symptom onset</b> (median + IQR)	3 (3-4)	4 (3-5)	<b>0.023</b>	0.566
<b>Sampling score</b> (median + IQR)	7 (6-7.75)	6 (5-8)	0.217	


\*Includes moderate, low, and zero emitters. All values are represented as the number of patients unless specified otherwise. IQR-Interquartile range

**Supplementary Table 4 – Comparison Between Single infection and Multiple infection households**

Description	Single infection households (N=22)	Multiple infection households (N=67)	p-value	Adjusted p-value (Multivariate Analysis)
<b>Age</b> (median + IQR)	39 (30-50)	40 (31-49)	0.764	0.432
<b>Gender</b>				
Male	10	39		
Female	12	28	0.331	
<b>Vaccine status</b>				
Cs-D1	7	18	0.065	
Cs-D2	2	26	<b>0.018</b>	0.227
Cx-D2	6	17	0.119	Adjusted for Age, No of Symptoms, Fever as a symptom, Days between the last dose of vaccination to infection and adjusted for the effect of Days between the last dose of vaccination to infection in CS-D2 patients
Unvaccinated	7	4		
<b>Days between last dose of vaccination to infection</b> (median + IQR)	58 (26-77)	63 (37-87)	<b>0.021</b>	0.401
<b>Number of symptoms</b>	3 (1-4)	3 (2-5)	0.236	0.259
<b>Types of symptoms</b>				
Fever	9	36	0.221	0.786
Cough	12	17	0.67	
Sore throat	6	37	>0.999	
Gastric problems	11	4	>0.999	
Cold	4	20	0.408	
<b>Viral load in mask</b> (Log Value, median + IQR)	2.2 (1.6-3.7)	2.8 (1.6-4.1)	0.371	
<b>Viral load in Swab</b> (Log Value, median + IQR)	4.4 (2.-6.1)	5.6 (4.5-6.6)	<b>0.011</b>	
<b>Ct value at diagnosis</b> (median + IQR)	21 (17-24)	20 (16.5-24)	0.337	
<b>Family type</b>				
Nuclear	8	34		
Joint	14	33	0.326	
<b>Days post symptom onset</b> (median + IQR)	4 (3-5)	4 (3-5)	0.495	
<b>Antivirals Taken</b>	12	43	0.455	


Single infection Household – Only study patient infected with SARS-CoV-2, multiple infection Household – Study patient + Household member/s infected with SARS-CoV-2, IQR-Interquartile range

## Supplementary Figure 1



**Supplementary Figure 1:** Scatter plot depicting the NPS Ct value on X-axis and mask viral load on Y-axis **1A**- at Enrolment and **1B** – Follow up

**Supplementary Figure 2**



**Supplementary Figure 2 – Probit Analysis** – The graphs describe the probability of being mask positive (2A), swab positive (2B) or a high emitter (2C) on any day after the symptom onset of SARS-CoV-2 infection as calculated by Probit (MedCalc software, 20.019). The red lines highlight the probability of being mask (2A), swab (2B) positive or high emitter (2C) tenth day from symptom onset.